Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR Inventory
Raw materials, work in progress, and finished goods held for sale.
Citius Oncology, Inc.NASDAQ: CTOR
Inventory · Q2 FY2026 · quarter ended Mar 2026
Inventory rises 47.7% from a year ago
Inventory stood at $22.66M at the end of Q2 FY2026, up 47.7% from a year earlier and up 0.1% from the prior quarter.
Context
- Inventory amounted to 22.5% of total assets at the end of Q2 FY2026, up 5.7 pp from a year earlier.
- Inventory increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether inventory keeps rising in the next quarterly balance sheet after a +47.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Inventory history
USD · from the balance sheet
- Latest · FY2025
- 22.29M USD
- Year-over-year change
- +169.5%
| Period | Period end | Inventory | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 22.29M | +169.5% |
| FY2024 | 2024-09-30 | 8.27M | — |
| FY2023 | 2023-09-30 | 0 | — |
| FY2022 | 2022-09-30 | 0 | — |
Inventory vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's Mar 2026 inventory of $22.66M is the 2nd highest of the 10 companies compared; the peer median is $0.
- Its year-over-year change of +47.7% is the lowest of 4, against a peer median of +50.7%.
- Inventory amounts to 22.5% of total assets for CTOR, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $23.1M | +50.7% | +22.4% | 34.9% | |
CTORCitius Oncology, Inc. | Mar 2026 | $22.66M | +47.7% | — | 22.5% |
| Mar 2026 | $18.19M | +54.0% | -6.2% | 21.0% | |
| Mar 2026 | $4.53M | +50.2% | +51.5% | 1.5% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding CTOR) | $0 | +50.7% | +22.4% | 0.0% | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.